GemVax & KAEL Co., Ltd. engages in the production of chemical filters and gas scrubbers for semiconductors. It operates through the Environmental Pollution Control project and Bio business divisions. The Environmental Pollution Control project business division focuses on the manufacture of filters necessary for the semiconductor and display manufacturing process and the air pollution/odor prevention equipment business. The Bio business division refers to the preparation for phase 2 and 3 clinical trials at home and abroad for various indications such as Alzheimer's disease, benign prostatic hyperplasia, and progressive supranuclear palsy with GV1001, a telomerase-derived peptide-based new drug substance. The company was founded on March 10, 1998 and is headquartered in Daejeon, South Korea.